Introduction {#sec0005}
============

The coronavirus (COVID-19) has rapidly spread and swept across most countries worldwide since the first case was detected. There is currently no effective antiviral therapy or immune-based treatment for COVID-19, especially for asymptomatic or mild patients who are recommended to self-care under home quarantine. However, severe cases rapidly increase in their progression from mild cases one week after onset and can develop into respiratory failure and acute respiratory distress syndrome (ARDS) on the basis of pneumonia ([@bib0215]). Therefore, there is an urgent challenge to prevent the transition of COVID-19 from mild to severe. Oxygen (O~2~) therapy has been widely used and strongly recommended for patients in hospitals and cabin hospitals in China; however, asymptomatic or mild COVID-19 has not been given sufficient consideration in the present therapeutic guidelines. Through reviewing the relevant literature and combining the characteristics of COVID-19, this study proposed that nocturnal O~2~ therapy could be administrated for patients diagnosed with COVID-19 regardless of hypoxia, and may be helpful in preventing disease progression by inhibiting rapid replication of the virus and improving the body\'s antiviral ability.

An oxygen-rich environment may disrupt virus replication {#sec0010}
========================================================

Viruses rely on the host cell's infrastructure and metabolism to complete their life cycle. Many viruses can re-programme host cellular metabolism for their replication. For instance, it has been shown that adenoviral, cytomegalovirus, vaccinia virus, and Kaposi's sarcoma-associated herpesvirus decrease oxidative phosphorylation and induce glycolysis, which provide a large carbon source for the synthesis of nucleotides and amino acids needed to replicate the virus ([@bib0190], [@bib0230], [@bib0120], [@bib0045]). The mechanisms of viral activation of glycolysis are sophisticated. Some investigations have found that hepatitis B virus, H1N1 virus, vaccinia virus, and human papillomavirus can stabilise hypoxia-inducible factor 1α (HIF-1α) from degradation under normoxic conditions ([@bib0120], [@bib0175], [@bib0065], [@bib0125]). It is well-known that HIF-1α is a transcriptional activator of cellular metabolic state by hypoxia, and stabilising HIF-1α induces metabolic transformation from mitochondrial biogenesis to glycolysis. Furthermore, evidence has also revealed that hypoxia could enhance human B19 erythrovirus gene expression and hepatitis C virus replication ([@bib0155], [@bib0200]). These results indicate that HIF-1α may play a pivotal role in promoting virus replication. From the analysis of clinical data, the development of COVID-19 is a process of gradual hypoxia, which is more conducive to virus replication. However, HIF-1α activity is suppressed by hydroxylate two proline residues within HIF-1α under sufficient O~2~ conditions ([@bib0030]). Although there is no direct evidence that O~2~ supplementation could reduce HIF-1α expression in virus-infected cells, researchers have reported that HIF-1α expression in the kidney significantly decreased after exposure to high O~2~ concentrations in vivo ([@bib0160]). A recent study also showed that hyperoxic breathing of 60% O~2~ markedly down-regulated HIF-1α expression in tumour cells and inhibited tumour growth compared with breathing 20% O~2~ ([@bib0210]).

Thus, this study speculated that early and appropriate O~2~ therapy for COVID-19 patients could disrupt virus replication by decreasing HIF-1α.

Oxygen supplementation can improve antiviral immune response {#sec0015}
============================================================

The median time from the initial symptoms to dyspnoea is 5.0 days ([@bib0220]), which may be associated with cytokine storm and result in multiorgan damage or failure. Early robust virus replication disrupts the immune response and contributes to the subsequent inflammatory storm; however, the mechanism has not been fully elucidated. For virus infection, host factors initiate an immune response against the virus. A major component of innate immunity is the type I interferon (IFN-I) response. IFN-I can activate transcription factors and induce expression of IFN-stimulated genes ([@bib0105]), thus promoting host cells to fight against the virus infection. However, SARS-CoV, which is similar to SARS-CoV-2, has been proven to inhibit the production of IFN-I in cell and animal models ([@bib0180]). Therefore, it is imperative to understand the mechanism of the virus to overcome the interferon response and in order to take appropriate measures. Researchers recently demonstrated that lactate derived from glycolysis is the first metabolite directly combined with mitochondrial antiviral-signalling, and the lactate aggregation due to glycolysis or by increased lactate dehydrogenase (LDH) may be a potential mechanism for the virus to inhibit IFN-I production ([@bib0240]). It is worth noting that clinical studies have shown that elevated LDH or lactate levels have been detected in some patients with viral infection, especially those with poor prognosis ([@bib0090], [@bib0035]). According to clinical data from patients infected with SARS-CoV-2 in Wuhan, China, LDH increased in 29 of 40 participants (73%), of which 12 of 13 (92%) were in ICU and 17 of 27 (63%) were not in ICU ([@bib0085]). Thus, inhibiting glycolysis and reducing lactate production are expected to activate antiviral immunity in the early stages of virus infection. As previously mentioned, O~2~ can affect the activation of HIF-1α and reduce glycolysis. In addition, O~2~ could reduce the accumulation of lactate by accelerating its degradation. Therefore, early and appropriate O~2~ therapy for COVID-19 patients could be beneficial to release interferons and activate the antiviral immune response.

Immune cells such as CD8+effector T cells and natural killer cells (NK) are believed to play a crucial role in antiviral immunity. However, the proportion of immune cells in the blood of most patients infected with SARS-CoV-2 is decreased. Recently, researchers detected the peripheral blood lymphocyte subsets in patients with COVID-19 and found that the reduction in rates of CD4 + T, CD8 + T and NK cells were 60.16%, 68.3% and 36.59%, respectively ([@bib0205]), which greatly weaken the body's resistance to the virus.

Until now, no specific strategy has been recommended to improve the body's immunity to deal with early COVID-19. Concurrently, the therapeutic effect of O~2~ therapy in severe cases has prompted investigation into the impact of O~2~ on the immune system. Functional T-cell exhaustion has been demonstrated in patients with COVID-19, especially in severe cases, which is associated with higher levels of PD-1 ([@bib0050]). PD-1 is considered as a marker of T-cell exhaustion and previous studies have confirmed that blocking PD-1 / PD-L1 can restore T-cell function and accelerate virus clearance ([@bib0185]). Recently, researchers have found that PD-L1 expression can be controlled by HIF-1α both in mouse myeloid-derived suppressor cells and in the sepsis model. Silencing HIF-1a has been shown to reduce the expression of PD-L1 in monocytes and restore T-cell proliferation ([@bib0020], [@bib0130]). It is noteworthy that a previous analysis suggested that sufficient O~2~ could reduce HIF-1α expression, and respiratory hyperoxia was also proven to reverse immunosuppression by decreasing PD-L1 expression levels in a cancer mouse model ([@bib0165]). Moreover, Atkuri et al. reported that T-cell proliferation was significantly higher at atmospheric O~2~ levels (20% oxygen) than at physiological O~2~ levels (5% or 10% oxygen) when lymphocytes were cultured in vitro in response to external stimuli ([@bib0010]). A recent study revealed that breathing 60% O~2~ increased activities of T and NK cells, and decreased immunosuppressive molecules in a murine lung cancer model ([@bib0070]). Some researchers have also demonstrated that lymphocytes have higher proliferation efficiency in conditions of rich O~2~ compared with hypoxia ([@bib0225], [@bib0015]). Accordingly, it is tempting to speculate that sufficient O~2~ may improve the antiviral ability of patients with early COVID-19 by increasing the abundance and activities of immune cells.

Early oxygen intervention may reduce the up-regulated expression of ACE2 caused by hypoxia {#sec0020}
==========================================================================================

ACE2 is a cell membrane-associated enzyme belonging to the renin-angiotensin system and is expressed more in the kidneys and heart than that in the lungs (<https://www.ncbi.nlm.nih.gov/gene/59272>). It has been confirmed that SARS-CoV-2 uses ACE2, the same cell entry receptor of SARS-CoV, to enter the target cell ([@bib0245]). Thus, previous research on SARS-CoV may be helpful to understand COVID-19. One study showed that the SARS-CoV genome was found in the heart of 35% of the patients (7 of 20), demonstrating that a heart attack was associated with earlier death ([@bib0140]). A study on renal function of patients with SARS-CoV also indicated that acute renal impairment caused by SARS-CoV was related to high mortality ([@bib0170]). Moreover, according to the recent clinical data, the rate of renal impairment is remarkably higher in patients with COVID-19 compared with SARS-CoV ([@bib0110]). These multiple lines of evidence indicate that COVID-19 can infect the heart and renal system by ACE2 and cause serious damage in patients. Therefore, reducing the expression of ACE2 in organs in the early stages of COVID-19 infection could inhibit virus invasion. Research shows that hypoxia could increase the transcription of ACE2 by increasing SIRT1 expression on Huh7 cells ([@bib0040]) and up-regulate the expression of ACE2 in an HIF-1α‐dependent manner on CD 34^+^ cells ([@bib0095]). In pulmonary vascular smooth muscle cells, hypoxia has also been shown to up-regulate ACE2 expression ([@bib0235]). Researchers ([@bib0080]) have also found that the SARS-CoV infection significantly enhanced the expression of hypoxia upregulated 1gene as early as 6 hours, and patients with novel coronavirus pneumonia have already appeared anoxia in the early stages. However, the symptoms of dyspnoea do not appear until late in the disease course, which is probably due to hypoxia with accompanying hypocapnia ([@bib0135]). Thus, management of hypoxia in the early stages should delay the progression of COVID-19. Oxygen supplementation could increase the partial pressure of O~2~ in arterial blood by driving pressure for O~2~ and improve tissue oxygenation ([@bib0115]), which has been proven to improve function in the ischaemic myocardium ([@bib0100]). Oxygen therapy has also been reported to reduce renal vascular resistance and increase blood flow in patients with hypoxaemia ([@bib0025]). Therefore, early appropriate O~2~ therapy for COVID-19 patients may reduce the invasion of virus by increasing O~2~ content of blood against the up-regulated expression of ACE2 in tissues and organs caused by hypoxia.

Nocturnal oxygen therapy may delay the progression of COVID-19 {#sec0025}
==============================================================

Since cytokine storm is currently considered to be the primary cause of acute exacerbation of COVID-19, early intervention should be taken to inhibit or reduce the excessive production of inflammatory cytokines. The production of cytokines in human whole blood shows diurnal rhythmicity. The production of pro-inflammatory cytokines -- including IFN-γ, TNF-a, IL-1 and IL-12 -- peaks at night and early morning when plasma cortisol is lowest ([@bib0145]). Evidence has shown that whole blood stimulation with lipopolysaccharide (LPS) in vitro at night and early in the morning displayed increased cytokine and chemokine levels in samples from healthy volunteers compared with during daylight ([@bib0150]); a subsequent study in humans in vivo has also confirmed this ([@bib0005]). Furthermore, in a vesicular stomatitis virus murine encephalitis model where mice infection occurring at the start of the rest period showed higher mortality than infection at the start of the active period was associated with increased numbers of inflammatory cells ([@bib0060]). Therefore, a reduction of nocturnal pathogen exposure or replication is expected to inhibit the production of inflammatory factors. However, the rate of virus replication in the host may accelerate in the resting phase, according to Edgar et al., who showed that mice infected with murid herpesvirus at the start of the rest phase exhibited 10-fold higher viral loads than mice infected just before their active phase ([@bib0055]). However, most studies have focused on the time of primary encounter with the antigen. It still needs to be investigated whether virus replication is related to time of day, especially after a virus infects the host. Moreover, a recent study reported that SARS-CoV-2 from the nasal cavity is likely to be aspirated into the deep lung via gastro-oesophageal reflex-associated aspiration, which may be an important route to lung infection and usually occurs at night ([@bib0075]). Therefore, limiting virus replication at night would be a valid therapeutic strategy. Combined with a previous analysis, it is speculated that nocturnal O~2~ therapy could delay the progression of COVID-19 by inhibiting nocturnal virus replication.

Conclusion {#sec0030}
==========

The number of severe COVID-19 patients continues to increase, leading to an extremely increased demand on medical resources and requiring comprehensive treatment. Therefore, effective and safe interventions are urgently needed to prevent COVID-19 from developing from mild to severe. Based on the clinical data and literature analysis, it was proposed that O~2~ therapy could inhibit virus replication, regulate autoimmunity and decrease ACE2 expression in tissues. Since the virus may speed up invasion at night and increase over-production of inflammatory cytokines, combined with the fact that patients with lung diseases are prone to have hypoxia during sleep ([@bib0195]), it is recommend that nocturnal O~2~ therapy be given as a therapeutic option for patients under home quarantine. Since nocturnal O~2~ therapy is not a new concept and has been widely used in COPD patients, it is safe and easy to use in clinical practice (a home O~2~ concentrator is enough for a patient).
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